Chapter Two Renal function measures in the adolescent NHANES population
|
|
- Morgan Boone
- 6 years ago
- Views:
Transcription
1 0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you will so exert yourself in youth, that your old age will not lack sustenance. LeoNARDo da Vinci Vol 1 ckd Ch pg 49
2 ContENts Characteristics of U.S. adolescents 4 Associations of abnormal GFR 6 Trends in renal function 8 Summary In adults, population-based studies over the last decade have shown that chronic kidney disease (CKD) is much more prevalent than previously believed. Although kidney function typically declines with age, rising burdens of obesity and hypertension have been implicated as modifiable contributors to the substantial burden of CKD in adults. As successive surveys from the National Health and Nutrition Examination Survey (NHANES) show that these risk factors are rapidly becoming more prevalent in U.S. children and adolescents, there is a clear need for studying kidney function in community-dwelling adolescents. Unfortunately, very little communitybased research has been performed in this area. It is unknown, for example, whether adults, children, and adolescents share the same risk factors for CKD, and whether the burden of CKD has changed over the years. In this regard, NHANES, a representative sample of the non-institutionalized U.S. population, is a valuable resource, as serum creatinine and urinary albumin-creatinine (ACR) levels have been measured in each cycle, and cystatin C levels have been measured in some cycles. In Figure.1 we define the NHANES samples for the adult and adolescent populations, including the cohorts and the laboratory equipment used for the serum creatinine measurements and the cystatin C assay. The adolescent population was included in the random sample of individuals age 1 9, as were all males with a creatinine level greater than 1. mg/dl and females with a level greater than 1.0 mg/dl. To address the definition of normal kidney function in the adolescent population, we define a group with blood pressure less than 10/80 mmhg, without hypertension or self-reported diabetes, and not currently pregnant or menstruating. Comparisons between the adolescent participants meeting these reference criteria and those not included are shown in Table.a. There are significant differences in estimated glomerular filtration rate (egfr, calculated by the Schwartz formula) and in serum creatinine and cystatin C levels. Other differences include a slight difference in mean age, and, in the non-reference population, greater height, greater weight, and higher systolic and diastolic blood pressures. In addition, racial differences reflect the burden of hypertension and diabetes in the African American adolescent population, consistent with data reported on the degree of obesity and Type diabetes in this population. Based on these restrictions, it appears that the normal average creatinine value in healthy adolescents is 0.71 mg/dl, and the estimated GFR is ml/min/1.73 m. The urine albumin/creatinine ratio is 8 mg/g, a level higher than that in the adult population. The distribution of serum creatinine levels varies with age in the reference population, in a manner suggesting a role for differences in muscle mass. The distribution of cystatin C levels, however, is similar across age groups. For the Schwartz egfr, the 9 th percent confidence interval ranges from 16 to 18, with levels slightly lower in females than in males. Generally, albumin/creatinine ratios in the adolescents are less than mg/g, the 7 th percentile of the reference group; percent, however, have levels greater than 0 mg/g, and. percent have levels higher than 10 mg/g. Since there were no repeat samples to address the Ch pg 0
3 consistency of albumin/creatinine ratios over time it is difficult to assess the meaning of these higher values. This being said, sampling theory would suggest that for every subject exhibiting an atypically high value on the day of sampling, another study subject exhibited atypically low values. Multivariate associations of declining egfr (as indicated by a lower creatinine-based Schwartz-formula egfr or a rising cystatin C level) include older age, female gender, African American race, Hispanic/Mexican ethnicity, and higher body mass index. Associations of higher log-transformed urinary albumin/creatinine levels include female gender, white race, lower body mass index, and higher systolic blood pressure. We next examine associations between kidney function and abnormal biochemical tests. Kidney function tests are relatively poor predictors of laboratory tests, being outside the 9 th percentile of the reported range in the NHANES adolescent cohort. There are some univariate continuous associations worth noting, in that a rising serum creatinine is associated with a lower bicarbonate level, higher serum phosphorus, and a hemoglobin level less than 1. g/dl. Under multivariate models, however, most biochemical abnormalities are not significant. The chapter concludes with data on trends in renal function measures. There has been a significant rise in serum creatinine levels, but no change in cystatin C levels. Body mass index has risen 4. percent, and there has been a significant increase in systolic blood pressure. It is certainly of concern that creatinine levels appear to have risen in U.S. adolescents. levels, however, have remained unchanged over a decade, and it is hard not to speculate about the role played by differences in measurement and validation strategies. Figure.1; see page 143 for analytical methods. 1i Laboratory analyses for serum creatinine & cystatin C levels in the NHANES population NHANES Routine creatinine: Roche/Hitachi 737 validation N = 00 per cycle. Participants age 60+. Roche coupled enzymatic assay. NHANES Routine creatinine: Roche/Hitachi 917 NHANES Routine creatinine: Roche/Hitachi 917 (001); Beckman Coulter Synchron LX0 (00) All participants age 60+. All males with creatinine > 1. mg/dl; all females with creatinine > 1.0 mg/dl. % random sample of all participants age <60. NHANES NHANES NHANES USRDS Annual Data Report 4 RENAL FUNCTIon MEASURES IN ADoLESCENTS Vol 1 ckd Ch pg 1
4 Among NHANES participants age 1 17, mean values were as follows: age, 14. years; height, cm; weight, 6.6 kg; serum creatinine, 0.7 mg/dl; serum cystatin C, 0.84 mg/l; ACR, 7. mg/g; and estimated glomerular filtration rate, ml/min/1.73 m. For purposes of assembling an overtly healthy reference population, adolescents with the following characteristics were excluded: obesity, systolic blood pressure greater than 10 mmhg, diastolic blood pressure greater than 80 mmhg, self-reported hypertension, self-reported diabetes, and pregnancy or menstruation at the time of testing. Discriminating characteristics of excluded adolescents included lower GFR, higher serum creatinine, higher serum cystatin C, older age, and a lower proportion of white subjects. Table.A; see page 143 for analytical methods. NHANES (cystatin C, ) participants age ai Characteristics of U.S adolescents age 1 17, NHANES (column percent; cystatin C, only) In reference population a All SE Yes SE No SE p-value Schwartz egfr ml/min/1.73 m Serum creatinine (mg/dl) 0.7 < < < Serum cystatin C (mg/l) b 0.84 < < Urinary ACR, mg/g Age (years) < Height (cm) Weight (kg) Body mass index (kg/m ) Systolic blood pressure (mmhg) Diastolic blood pressure, (mmhg) Female (%) Race/ethnicity (%) White African American Hispanic Other Obesity c (%) Systolic BP 10 mmhg (%) Diastolic BP 80 mmhg (%) Hypertension (%) Diabetes (%) Pregnant (%) Menstruating (%) Abbreviations: egfr, estimated glomerular filtration rate; ACR, albumin/creatinine ratio; BP, blood pressure; SE, standard error. Missing data: urinary ACR, 61; weight, 0; systolic and diastolic blood pressure, 13. a Reference population: blood pressure <10/80 mmhg, without a diagnosis of hypertension, without self-reported diabetes, and not currently pregnant or menstruating. b was measured in the NHANES survey. c Obesity defined as a z-score for weight-to-height 1.64 on the CDC growth reference tables in 000. Cells with 0.0 values represent excluded criteria definitions. Ch pg
5 F i Serum creatinine percentiles in the reference population, by age & gender, NHANES years 14-1 T 3i egfr (ml/min/1.73 m) Male Female egfr (Schwartz formula) percentiles in the reference population, by age & gender, NHANES i 1-13 years 14-1 i ACR (mg/g) (mg/l) ACR percentiles in the reference population, by age & gender, NHANES years Male Female Percentiles Percentiles ere we illustrate distributions of serum cystatin C levels. For ages 1 13, the 9th percentiles for males and females are 1.06 and 0.98 mg/l; for ages 14 1, 1.06 and 1.01 mg/l, and for ages 16 17, 1.07 and 0.9 mg/l. Regarding the 9th percentile for serum cystatin C in the healthy reference population, it is apparent that values remain stable with age, as does the discrepancy between males and females. Figure.4; see page 143 for analytical methods. NHANES participants age H 14-1 Male Female Male Female Percentiles percentiles in the reference population, by age & gender, NHANES Percentiles years his figure presents distributions of urinary ACR levels. For ages 1 13, the 9th percentiles for males and females are.6 and 16.1 mg/g; for ages 14 1, 86. and mg/g; and for ages 16 17, 79.1 and 69.4 mg/g. In terms of the 9th percentile for ACR in the healthy reference population, it is apparent that at, ages 1 13, values in males are lowest, values in females are highest, and the discrepancy between males and females is highest. Figure.; see page 143 for analytical methods. NHANES participants age T 009 USRDS Annual Data Report Serum creatinine (mg/dl) 1. his figure illustrates distributions of Schwartzformula, creatinine-based GFR levels. For ages 1 13, the fifth percentiles for males and females are 118 and 11 ml/min/1.73 m; for ages 14 1, 11 and 106, and for ages 16 17, 111 and 97. Regarding the fifth percentile for egfr in the healthy reference population, it is apparent that values fall after age 1, and that the discrepancy between males and females is widest at age Figure.3; see page 143 for analytical methods. NHANES participants age Characteristics of U.S. adolescents 4 Renal function measures in adolescents igure. shows distributions of serum creatinine levels in the adolescent NHANES population. For ages 1 13, the 9th percentiles for males and females are 0.79 and 0.78 mg/dl; for ages 14 1, 0.98 and 0.86 mg/dl; and for age 16 17, 1.08 and 0.89 mg/dl. Regarding the 9th percentile for serum creatinine in the healthy reference population, it is apparent that values increase with age, as does the discrepancy between males and females. Figure.; see page 143 for analytical methods. NHANES participants age Vol 1 ckd Ch pg 3
6 These tables look at associations of renal function measures in U.S. adolescents. With unadjusted linear regression analysis, there are inverse relationships between the Schwartz-formula, creatinine-based estimated glomerular filtration rate (egfr) and age, female gender, African American race, Hispanic ethnicity, body mass index (BMI), and diastolic blood pressure levels. With the exception of diastolic blood pressure, these findings persist in adjusted models. Also using unadjusted linear regression analysis, there are inverse relationships between cystatin C levels and female gender, African American race, Hispanic ethnicity, and systolic blood pressure levels. With covariate adjustment, there are inverse relationships with female gender, African American race, and Hispanic ethnicity, and a direct relationship with BMI. Looking at log-transformed urinary albumin/creatinine (ACR) levels, with unadjusted linear regression analysis there are inverse relationships with age, African American race, and BMI, and direct relationships with female gender and diastolic blood pressure. With covariate adjustment, there are inverse relationships with African American race and BMI, and direct relationships with female gender and systolic blood pressure. TablES.b d; see page 143 for analytical methods. NHANES (.b &.d) & NHANES (.c) participants age 1 17; reference: male, white. bi Unadjusted Adjusted Coeff. SE p-value Coeff. SE p-value Age, per 1. years < < Female < < African American < < Hispanic/Mexican < < Other race BMI, per.0 kg/m < Systolic BP, per.8 mmhg Diastolic BP, per 6.9 mmhg < ci Unadjusted Adjusted Coeff. SE p-value Coeff. SE p-value Age, per 1. years Female < < African American < < Hispanic/Mexican < < Other race BMI, per.0 kg/m 0.01 < < Systolic BP, per.8 mmhg 0.01 < < 0.01 < Diastolic BP, per 6.9 mmhg > < < 0.01 < di Associations of renal function measures in U.S. adolescents in the general population: egfr (Schwartz formula), NHANES Associations of renal function measures in U.S adolescents in the general population: cystatin C, NHANES Associations of renal function measures in U.S adolescents in the general population:, NHANES Unadjusted Adjusted Coeff. SE p-value Coeff. SE p-value Age, per 1. years Female < < African American Hispanic/Mexican Other race BMI, per.0 kg/m < < Systolic BP, per.8 mmhg Diastolic BP, per 6.9 mmhg < Ch pg 4
7 ei Renal function measures as continuous variables to detect blood pressure & laboratory abnormalities in U.S. adolescents, NHANES (cystatin C, ) Unadjusted OR CI p-value C-statistic Adjusted OR CI T p-value C-statistic Potassium 4.6 mmol/l HCO mmol/l < < Uric acid 7.14 mg/dl < < < < < < < Systolic BP 1.81 mmhg Diastolic BP 76.0 mmhg Hemoglobin 1.0 g/dl 009 USRDS Annual Data Report Phosphorus.3 mg/dl Associations of abnormal GFR 4 Renal function measures in adolescents his table shows associations between measures of renal function, as continuous variables, and potassium, bicarbonate, phosphorus, uric acid, blood pressure, and hemoglobin levels above or below the 9th percentiles of the overall population of adolescents. In general, as reflected by unadjusted C-statistics uniformly less than 0.80, renal function tests are poor discriminators of the presence or absence of these abnormalities. Regarding the different measures of renal function, rising serum creatinine levels are associated with a higher likelihood of abnormal bicarbonate, phosphorus, and hemoglobin, and a lower likelihood of abnormal uric acid, systolic blood pressure, and diastolic blood pressure. Schwartzformula, creatinine-based egfr levels are associated with a lower likelihood of abnormal phosphorus and a higher likelihood of abnormal diastolic blood pressure; cystatin C levels are associated with a lower likelihood of abnormal potassium and uric acid and a higher likelihood of abnormal hemoglobin; and log-transformed ACR levels are associated with a higher likelihood of abnormal potassium and uric acid levels. With multivariate analysis, serum creatinine is associated with a lower likelihood of abnormal uric acid and diastolic blood pressure, and a higher likelihood of abnormal hemoglobin; egfr levels are associated with a higher likelihood of abnormal uric acid and a lower likelihood of abnormal hemoglobin; cystatin C levels are associated with a lower likelihood of abnormal uric acid and systolic blood pressure; and log-transformed ACR levels are associated with none of these abnormalities. Table.e; see page 143 for analytical methods. NHANES (cystatin C, ) participants age Vol 1 ckd Ch pg
8 fi Trends in renal function measures over time in U.S. adolescents in the general population, NHANES (cystatin C, ) NHANES NHANES NHANES Mean SE Mean SE Mean SE p-value (mg/dl) < (mg/l) Not measured 0.30 Log (ACR (mg/g) Age (years) Height (cm) Weight (kg) Body mass index (kg/m ) Systolic BP (mmhg) Diastolic BP (mmhg) < Female (%) Race/ethnicity (%) < White African American Hispanic Other This table compares the characteristics of U.S. adolescents in three NHANES cohorts. While mean age and height are similar in all three timeframes, body weight, body mass index, and systolic blood pressure have each increased. Regarding measures of renal function, serum creatinine levels rose from 0.70 mg/dl in to 0.73 mg/dl in the 003. measurements were not performed in the period, and no difference is observed in the and populations. Urinary albumin/creatinine ratios, in contrast, increased from.08 mg/g in to.4 mg/g in Table.f & figures.6 8; see page 143 for analytical methods. NHANES (.f,.6,.8) & NHANES (.7) participants age Ch pg 6
9 Trends in serum creatinine in U.S. adolescents in the general population, NHANES i Trends in serum cystatin C in U.S. adolescents in the general population, NHANES Mean serum cystatin C (mg/l) cystatin C not available in i Trends in log-transformed urinary ACR in U.S. adolescents in the general population, NHANES Mean log (ACR (mg/g)) USRDS Annual Data Report Trends in renal function 4 Renal function measures in adolescents Mean serum creatinine (mg/dl) 6i Vol 1 ckd Ch pg 7
10 chapter summary Mean values for age, height, & weight in U.S. adolescents age kg, respectively..a 1 17 were 14. years, cm, & 6. Among U.S. adolescents age 1 17 in , means for serum creatinine & serum cystatin C were 0.7 mg/dl & 0.84 mg/l, respectively..a Rising serum creatinine levels are associated with a higher likelihood of abnormal bicarbonate, phosphorus, & hemoglobin..e Rising serum creatinine levels are associated with a lower likelihood of abnormal uric acid, systolic blood pressure, & diastolic blood pressure..e When comparing the characteristics of U.S. adolescents in three NHANES cohorts, mean age & height are similar in all three timeframes..f Among U.S. adolescents in three NHANES cohorts, body weight, body mass index, & systolic blood pressure have each increased..f summary Ch pg 8
A n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationKEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.
28 S u m m a r y F i g u r e s American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 29:pp S32 S44. S32 Definitions S33 Data Analyses Diabetes Self-reported diabetes, self reported diabetic retinopathy,
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationKEEP 2009 Summary Figures
S4 29 Summary Figures American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 21:pp S4-S57 S41 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving
More informationTwo: Chronic kidney disease identified in the claims data. Chapter
Two: Chronic kidney disease identified in the claims data Though leaves are many, the root is one; Through all the lying days of my youth swayed my leaves and flowers in the sun; Now may wither into the
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationKEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64
211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated
More informationKEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56
21 Summary Figures S32 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated blood glucose (WHO); fasting blood sugar
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationSupplementary Online Content
Supplementary Online Content Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559. eequation. Applying the
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population In light of the 2017 blood pressure guidelines from the American College of Cardiology/American Heart Association (ACC/AHA), this year we examine hypertension control
More informationSummary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup
http://www.kidney-international.org & 2013 DIGO Summary of Recommendation Statements idney International Supplements (2013) 3, 5 14; doi:10.1038/kisup.2012.77 Chapter 1: Definition and classification of
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
COMPARISON OF TREATING METABOLIC ACIDOSIS IN CKD STAGE 4 HYPERTENSIVE KIDNEY DISEASE WITH FRUITS & VEGETABLES OR SODIUM BICARBONATE This was a 1-year, single-center, prospective, randomized, interventional
More informationKEEP 2.0 Annual Data Report Chapter Five
KEEP 2. Annual Data Report Chapter Five Figure 5.1 percent distribution of KEEP participants with elevated serum creatinine levels, overall & by age 16 Percent of participants 12 8 4 All
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationH e alth his to r y. Chapter 3 Health history. s29
3 H e alth his to r y My mama died from undetected kidney disease in Oct. 22. It was only after 2 years of being treated for high blood pressure, a blood test [was done] to check on her kidneys. She went
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationSupplementary Online Content
Supplementary Online Content Clark WF, Sontrop JM, Huang S-H et al. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: the CKD WIT Randomized
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationAshberyh CHAPTER. John
A knowledge that people live close by is, I think, enough. And even if only first names are ever exchanged The people who own them seem rock-true and marvelously self-suficient. John Ashberyh The Ongoing
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationThe incidence and prevalence of hypertension
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George
More informationRenal tubular secretion in chronic kidney disease: description, determinants, and outcomes. Astrid M Suchy-Dicey
Renal tubular secretion in chronic kidney disease: description, determinants, and outcomes Astrid M Suchy-Dicey A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
More information2017 USRDS ANNUAL DATA REPORT KIDNEY DISEASE IN THE UNITED STATES S611
Healthy People 2020 In this chapter, we examine data for 11 Healthy People 2020 (HP2020) objectives 10 for CKD and one for diabetes spanning 20 total indicators for which the USRDS serves as the official
More informationEffect of Saxagliptin on Renal Outcomes in the SAVOR TIMI- 53 study- Appendixes:
Effect of Saxagliptin on Renal Outcomes in the SAVOR TIMI- 53 study- Appendixes: Appendix Table 1: Number and % of patients at the saxagliptin and placebo arms, according to egfr and on treatment ACR groups
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationThe relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan
Environ Health Prev Med (2011) 16:191 195 DOI 10.1007/s12199-010-0183-9 SHORT COMMUNICATION The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan Nobuyuki
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationChapter 3: Morbidity and Mortality in Patients with CKD
Chapter 3: Morbidity and Mortality in Patients with CKD In this 2017 Annual Data Report (ADR) we introduce analysis of a new dataset. To provide a more comprehensive examination of morbidity patterns,
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationResearch Article Comparison of CKD-EPI Cystatin C and Creatinine Glomerular Filtration Rate Estimation Equations in Asian Indians
International Nephrology Volume 24, Article ID 746497, 8 pages http://dx.doi.org/.55/24/746497 Research Article Comparison of CKD-EPI Cystatin C and Creatinine Glomerular Filtration Rate Estimation s in
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationChapter Two Incidence & prevalence
Chapter Two Incidence & prevalence Science is the observation of things possible, whether present or past. Prescience is the knowledge of things which may come to pass, though but slowly. LEONARDO da Vinci
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationClinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria
Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
More informationOnline clinical pathway for chronic kidney disease (CKD) in primary care. February 27, 2015 Dr. Kerry McBrien University of Calgary
Online clinical pathway for chronic kidney disease (CKD) in primary care February 27, 2015 Dr. Kerry McBrien University of Calgary FACULTY/PRESENTER DISCLOSURE Faculty: Kerry McBrien Relationships with
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationChapter 3: Morbidity and Mortality
Chapter 3: Morbidity and Mortality Introduction In this chapter we evaluate the morbidity and mortality of chronic kidney disease (CKD) patients continuously enrolled in Medicare. Each year s analysis
More informationPrimary Care Approach to Management of CKD
Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury In 2015, 4.3% of Medicare fee-for-service beneficiaries experienced a hospitalization complicated by Acute Kidney Injury (AKI); this appears to have plateaued since 2011
More informationDiabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES)
Diabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004 Adam T. Whaley-Connell, DO, MSPH, 1 James R. Sowers, MD, 1 Samy
More informationSection 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic
More informationHypertension. Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008
Hypertension Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 Brent M. Egan, MD; Yumin Zhao, PhD; R. Neal Axon, MD; Walter A. Brzezinski, MD; Keith C. Ferdinand,
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationZuni Health Initiative
ZUNI JEWELRY Zuni Health Initiative Raj Shah-University of New Mexico vshah@salud.unm.edu Do' tse'mak i:k'oshudu, elek'yanna!!! May you feel better, everything will be alright!!! OBJECTIVES Describe the
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationARIC Manuscript Proposal # 1518
ARIC Manuscript Proposal # 1518 PC Reviewed: 5/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1. a. Full Title: Prevalence of kidney stones and incidence of kidney stone hospitalization in
More informationComposite Performance Report
Composite Performance Report 10 9 91% 8 7 65% 68% 65% 6 56% 5 4 3 2 44% 37% 48% 31% 19% 29% 1 6% Key: Report Measure Name Cohort Target Cohort Definition Formula 1 Control Blood Pressure All patients who
More informationPRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME
PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME 217 American Society of Nephrology Meeting Geoffrey A. Block 1, Pablo E. Pergola 2, Lesley
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,
More information(KFTs) IACLD CME, Monday, February 20, Mohammad Reza Bakhtiari, DCLS, PhD
Kidney Function Tests (KFTs) IACLD CME, Monday, February 20, 2012 Mohammad Reza Bakhtiari, DCLS, PhD Iranian Research Organization for Science & Technology (IROST) Tehran, Iran Composition and Properties
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationDialysis Initiation and Optimal Vascular Access: Outcomes and Mortality
Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationMagnetic resonance imaging, image analysis:visual scoring of white matter
Supplemental method ULSAM Magnetic resonance imaging, image analysis:visual scoring of white matter hyperintensities (WMHI) was performed by a neuroradiologist using a PACS system blinded of baseline data.
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationChronic kidney disease (CKD) reportedly affects
AJH 2006; 19:608 614 Kidney A Comparison of Serum Creatinine Based Methods for Identifying Chronic Kidney Disease in Hypertensive Individuals and Their Siblings Andrew D. Rule, Steven J. Jacobsen, Gary
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationClinical Study Factors Associated with the Decline of Kidney Function Differ among egfr Strata in Subjects with Type 2 Diabetes Mellitus
International Endocrinology Volume 2012, Article ID 687867, 6 pages doi:10.1155/2012/687867 Clinical Study Factors Associated with the Decline of Kidney Function Differ among egfr Strata in Subjects with
More informationSupplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.
SUPPLEMENTAL MATERIAL Supplemental Table 1. Standardized Serum Creatinine Measurements Supplemental Table 2. List of ICD 9 and ICD 10 Billing Codes Supplemental Table 3. Sensitivity Analyses with Additional
More informationINDEX WORDS: Awareness; chronic kidney disease; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); estimated glomerular filtration rate.
KEEP 2010 Comparison of CKD Awareness in a Screening Population Using the Modification of Diet in Renal Disease (MDRD) Study and CKD Epidemiology Collaboration (CKD-EPI) Equations Manjula Kurella Tamura,
More informationHHS Public Access Author manuscript Am J Kidney Dis. Author manuscript; available in PMC 2017 July 05.
HHS Public Access Author manuscript Published in final edited form as: Am J Kidney Dis. 2017 March ; 69(3): 482 484. doi:10.1053/j.ajkd.2016.10.021. Performance of the Chronic Kidney Disease Epidemiology
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationRationale: Objectives: Indication: Diabetes Mellitus, Type 2 Study Investigators/Centers: 300 physicians in 292 clinics Research Methods: Data Source:
GSK Medicine: N/A Study No.: 112255 Title: A Korean, multi-center, nation-wide, cross-sectional, epidemiology study to identify prevalence of diabetic nephropathy in hypertensive patients with type 2 diabetes
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationSupplement: Summary of Recommendation Statements CHAPTER 1: DEFINITION AND CLASSIFICATION OF CKD
Supplement: Summary of Recommendation Statements CHAPTER 1: DEFINITION AND CLASSIFICATION OF CKD 1.1 DEFINITION OF CKD 1.1.1: CKD is defined as abnormalities of kidney structure or function, present for
More informationIs there an association between waist circumference and type 2 diabetes or impaired fasting glucose in US adolescents?
Is there an association between waist circumference and type 2 diabetes or impaired fasting glucose in US adolescents? Meghann M. Moore, RD, CD Masters Thesis Maternal & Child Health Track School of Public
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Age and Kidney Weight renal weight and thickening of the vascular intima Platt et al. Gerentology 1999;45:243-253
More informationNational Kidney and Urologic Diseases Information Clearinghouse (NKUDIC)
National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) A service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) Kidney
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More information